Vanguard Group
HCAT icon

Vanguard Group’s Health Catalyst HCAT Stock Holding History

Vanguard Group’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.6M Buy
4,434,387
+138,696
+3% +$379K ﹤0.01% 2935
2025
Q3 		$12.2M Buy
4,295,691
+119,117
+3% +$408K ﹤0.01% 2867
2025
Q2 		$15.7M Buy
4,176,574
+44,921
+1% +$177K ﹤0.01% 2670
2025
Q1 		$18.7M Sell
4,131,653
-263,078
-6% -$1.39M ﹤0.01% 2531
2024
Q4 		$31.1M Sell
4,394,731
-185,832
-4% -$1.48M ﹤0.01% 2371
2024
Q3 		$37.3M Buy
4,580,563
+53,583
+1% +$387K ﹤0.01% 2304
2024
Q2 		$28.9M Buy
4,526,980
+50,749
+1% +$326K ﹤0.01% 2380
2024
Q1 		$33.7M Sell
4,476,231
-1,031,741
-19% -$9.42M ﹤0.01% 2341
2023
Q4 		$51M Sell
5,507,972
-933,735
-14% -$7.63M ﹤0.01% 2182
2023
Q3 		$65.2M Buy
6,441,707
+78,823
+1% +$941K ﹤0.01% 2009
2023
Q2 		$79.5M Buy
6,362,884
+164,371
+3% +$1.96M ﹤0.01% 1972
2023
Q1 		$72.3M Buy
6,198,513
+128,985
+2% +$1.64M ﹤0.01% 1992
2022
Q4 		$64.5M Buy
6,069,528
+127,870
+2% +$1.23M ﹤0.01% 2040
2022
Q3 		$57.6M Buy
5,941,658
+636,395
+12% +$8.43M ﹤0.01% 2114
2022
Q2 		$76.9M Buy
5,305,263
+1,069,889
+25% +$18.2M ﹤0.01% 1976
2022
Q1 		$111M Sell
4,235,374
-47,365
-1% -$1.34M ﹤0.01% 1884
2021
Q4 		$170M Buy
4,282,739
+163,505
+4% +$7.45M ﹤0.01% 1703
2021
Q3 		$206M Buy
4,119,234
+617,003
+18% +$33.7M 0.01% 1590
2021
Q2 		$194M Buy
3,502,231
+530,293
+18% +$28.3M ﹤0.01% 1644
2021
Q1 		$139M Buy
2,971,938
+87,306
+3% +$4.23M ﹤0.01% 1776
2020
Q4 		$126M Buy
2,884,632
+267,430
+10% +$9.86M ﹤0.01% 1720
2020
Q3 		$95.8M Buy
2,617,202
+554,293
+27% +$18.8M ﹤0.01% 1702
2020
Q2 		$60.2M Buy
2,062,909
+1,170,020
+131% +$32.3M ﹤0.01% 1915
2020
Q1 		$23.3M Buy
892,889
+99,296
+13% +$3.03M ﹤0.01% 2211
2019
Q4 		$27.5M Buy
793,593
+67,917
+9% +$2.25M ﹤0.01% 2380
2019
Q3 		$23M Buy
+725,676
New +$28.6M ﹤0.01% 2420

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return

Vanguard Group's HCAT Position: Q4 2025 in Review

Vanguard Group increased its Health Catalyst (HCAT) stake by 3.2% in Q4 2025, buying an estimated $379K and bringing the position to 4,434,387 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2935.

Vanguard Group first reported a position in HCAT in Q3 2019 and has held it in 26 quarters since. The position peaked at $206M in Q3 2021. 136 funds tracked by Wall St. Rank hold HCAT as of Q4 2025.

  • Vanguard Group held 4,434,387 shares of Health Catalyst worth $10.6M as of Q4 2025.
  • Vanguard Group bought 138,696 Health Catalyst shares in Q4 2025, an estimated $379K.
  • Health Catalyst made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2935 holding.
  • Vanguard Group first reported a position in Health Catalyst in Q3 2019 and has held it in 26 quarters since.
  • Vanguard Group's Health Catalyst position peaked at $206M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.